Media stories about Dipexium Pharmaceuticals (NASDAQ:PLXP) have been trending somewhat positive on Saturday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Dipexium Pharmaceuticals earned a news impact score of 0.20 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.6645936583705 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of Dipexium Pharmaceuticals (NASDAQ PLXP) opened at 6.35 on Friday. The company’s market cap is $55.17 million. Dipexium Pharmaceuticals has a 52-week low of $5.60 and a 52-week high of $142.01. The company has a 50 day moving average of $6.46 and a 200-day moving average of $7.70.

PLXP has been the topic of a number of recent research reports. Redburn Partners raised Dipexium Pharmaceuticals to an “outperform” rating in a report on Tuesday, August 1st. UBS AG raised Dipexium Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $12.00 target price on the stock in a report on Monday, July 31st. Finally, Zacks Investment Research downgraded Dipexium Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 19th. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $7.00.

COPYRIGHT VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/09/02/dipexium-pharmaceuticals-plxp-earns-media-impact-score-of-0-20.html.

In other news, COO Gary L. Mossman purchased 7,273 shares of the business’s stock in a transaction that occurred on Wednesday, June 14th. The shares were acquired at an average cost of $6.88 per share, for a total transaction of $50,038.24. Following the completion of the acquisition, the chief operating officer now owns 78,255 shares in the company, valued at $538,394.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Michael J. Valentino purchased 29,091 shares of the business’s stock in a transaction that occurred on Wednesday, June 14th. The shares were purchased at an average price of $6.88 per share, for a total transaction of $200,146.08. Following the completion of the acquisition, the insider now owns 122,386 shares of the company’s stock, valued at approximately $842,015.68. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 69,091 shares of company stock valued at $475,346. 47.70% of the stock is currently owned by insiders.

Dipexium Pharmaceuticals Company Profile

PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.

Receive News & Stock Ratings for Dipexium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dipexium Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.